Updated Jul 16, 2026
Palleiko Benjamin L has filed 5 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $1.98M.
Benjamin L. Palleiko is the Chief Executive Officer of KalVista Pharmaceuticals, Inc., a company focused on developing oral therapies for rare diseases. He has been involved in multiple SEC filings related to the company's operations.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-11 | KALV | KalVista Pharmaceuticals, Inc. | D — Derivative transaction | 480.0K | $0.00 | |
| 2026-05-26 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 10.9K | $26.78 | $293K |
| 2026-05-26 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 23.2K | — | |
| 2026-05-19 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 1.1K | $26.76 | $30K |
| 2026-05-19 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 2.4K | — | |
| 2026-05-13 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 3.3K | $26.71 | $89K |
| 2026-05-13 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 7.1K | — | |
| 2026-04-20 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 9.6K | $20.22 | $193K |
| 2026-04-20 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 20.3K | — | |
| 2026-03-10 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 6.7K | $16.08 | $108K |
| 2026-03-10 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 15.6K | — | |
| 2026-02-25 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 10.0K | $15.57 | $156K |
| 2026-02-25 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 23.2K | — | |
| 2026-02-20 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 1.0K | $15.00 | $16K |
| 2026-02-20 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 2.4K | — | |
| 2026-02-13 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 3.4K | $15.70 | $53K |
| 2026-02-13 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 7.1K | — | |
| 2025-09-06 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 7.3K | $15.84 | $116K |
| 2025-09-06 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 15.6K | — | |
| 2025-08-21 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 10.9K | $13.22 | $145K |
Benjamin L. Palleiko is the Chief Executive Officer of KalVista Pharmaceuticals, Inc., a company focused on developing oral therapies for rare diseases. He has been involved in multiple SEC filings related to the company's operations.…
5 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 14 open-market sales ($1.98M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Palleiko Benjamin L profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.